Medtronic plc (MDT) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $16.59B (period ending 2013-04-26) to $36.36B (period ending 2026-04-24) — a 6.2% annual pace across 13 year(s) of filed history.
- Net margin compressed from 20.9% to 13.2% over that same span.
- Across 36 tracked quarters, the strongest was $9.02B (quarter ending 2026-01-23) and the weakest was $0 (quarter ending 2015-01-23).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $36.36B | 2026-04-24 | 10-K | 0001628280-26-044354 |
| Gross profit | $3.73B | 2020-04-24 | 10-K | 0001613103-20-000021 |
| Operating income | $6.47B | 2026-04-24 | 10-K | 0001628280-26-044354 |
| Net income | $4.80B | 2026-04-24 | 10-K | 0001628280-26-044354 |
| Diluted EPS | $3.73 | 2026-04-24 | 10-K | 0001628280-26-044354 |
| Total assets | $93.03B | 2026-04-24 | 10-K | 0001628280-26-044354 |
| Total liabilities | $42.96B | 2026-04-24 | 10-K | 0001628280-26-044354 |
| Cash & equivalents | $1.95B | 2026-04-24 | 10-K | 0001628280-26-044354 |
| Operating cash flow | $7.33B | 2026-04-24 | 10-K | 0001628280-26-044354 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $9.02B | 2026-01-23 | 10-Q | 0001628280-26-011107 |
| Operating income | $1.46B | 2026-01-23 | 10-Q | 0001628280-26-011107 |
| Net income | $1.14B | 2026-01-23 | 10-Q | 0001628280-26-011107 |
| Diluted EPS | $0.89 | 2026-01-23 | 10-Q | 0001628280-26-011107 |
| Total assets | $91.48B | 2026-01-23 | 10-Q | 0001628280-26-011107 |
| Total liabilities | $42.29B | 2026-01-23 | 10-Q | 0001628280-26-011107 |
| Cash & equivalents | $1.15B | 2026-01-23 | 10-Q | 0001628280-26-011107 |
| Operating cash flow | $1.09B | 2025-07-25 | 10-Q | 0001613103-25-000161 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
Medtronic plc (MDT), a global medical technology company, demonstrates a diverse business scale with annual revenues escalating from $16.59 billion in 2013 to $36.36 billion in 2026, reflecting a 6.2% annual growth rate over 13 years. This steady increase underscores the company’s market penetration and product innovation within the medical device sector. However, despite revenue expansion, net margins have contracted from 20.9% to 13.2%, indicating potential pressure on profitability amidst growing operations.
The multi-year trajectory reveals a pattern of robust revenue growth, albeit with diminishing returns in terms of net income margins. Investors should monitor whether Medtronic can stabilize or improve its margins as it continues to scale up. The most recent quarterly figures showcase resilience, with revenues reaching $9.02 billion and operating income at $1.46 billion, although net income stands at $1.14 billion, reflecting ongoing margin pressures.
In the upcoming filings, keen attention should be paid to Medtronic’s strategies for enhancing profitability alongside its growth ambitions. Specifically, watch for any initiatives aimed at controlling costs or increasing pricing power without compromising market competitiveness. The company’s ability to navigate this balance will be crucial in determining future financial health and shareholder value.
Source: SEC EDGAR company facts for CIK 0001613103 · filings index